3eyd: Difference between revisions
Jump to navigation
Jump to search
m Protected "3eyd" [edit=sysop:move=sysop] |
No edit summary |
||
| Line 1: | Line 1: | ||
[[ | ==Structure of HCV NS3-4A Protease with an Inhibitor Derived from a Boronic Acid== | ||
<StructureSection load='3eyd' size='340' side='right' caption='[[3eyd]], [[Resolution|resolution]] 2.30Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[3eyd]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Hepatitis_c_virus_subtype_1a Hepatitis c virus subtype 1a]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3EYD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3EYD FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BE8:[(1R)-2-CYCLOBUTYL-1-({[(1R,2S,5S)-3-(N-{[(1S)-2,2-DIMETHYL-1-{[METHYL(METHYLSULFONYL)AMINO]METHYL}PROPYL]CARBAMOYL}-3-METHYL-L-VALYL)-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEX-2-YL]CARBONYL}AMINO)ETHYL]BORONIC+ACID'>BE8</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | |||
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">ns3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=31646 Hepatitis C virus subtype 1a])</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3eyd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3eyd OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3eyd RCSB], [http://www.ebi.ac.uk/pdbsum/3eyd PDBsum]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Chronic hepatitis C infection is the leading causes for cirrhosis of the liver and hepatocellular carcinoma, leading to liver failure and liver transplantation. The etiological agent, HCV virus produces a single positive strand of RNA that is processed with the help of serine protease NS3 to produce mature virus. Inhibition of NS3 protease can be potentially used to develop effective drugs for HCV infections. Numerous efforts are now underway to develop potent inhibitors of HCV protease that contain ketoamides as serine traps. Herein we report the synthesis of a series of potent inhibitors that contain a boronic acid as a serine trap. The activity of these compounds were optimized to 200pM. X-ray structure of compound 17 bound to NS3 protease is also discussed. | |||
Potent inhibitors of HCV-NS3 protease derived from boronic acids.,Venkatraman S, Wu W, Prongay A, Girijavallabhan V, George Njoroge F Bioorg Med Chem Lett. 2009 Jan 1;19(1):180-3. Epub 2008 Nov 5. PMID:19022670<ref>PMID:19022670</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
== | |||
< | |||
[[Category: Hepatitis c virus subtype 1a]] | [[Category: Hepatitis c virus subtype 1a]] | ||
[[Category: Girijavallabhan, V | [[Category: Girijavallabhan, V]] | ||
[[Category: Njoroge, F G | [[Category: Njoroge, F G]] | ||
[[Category: Prongay, A J | [[Category: Prongay, A J]] | ||
[[Category: Venkatraman, S | [[Category: Venkatraman, S]] | ||
[[Category: Wu, W | [[Category: Wu, W]] | ||
[[Category: Boronic acid inhibitor]] | [[Category: Boronic acid inhibitor]] | ||
[[Category: Envelope protein]] | [[Category: Envelope protein]] | ||
Revision as of 11:38, 26 November 2014
Structure of HCV NS3-4A Protease with an Inhibitor Derived from a Boronic AcidStructure of HCV NS3-4A Protease with an Inhibitor Derived from a Boronic Acid
Structural highlights
Publication Abstract from PubMedChronic hepatitis C infection is the leading causes for cirrhosis of the liver and hepatocellular carcinoma, leading to liver failure and liver transplantation. The etiological agent, HCV virus produces a single positive strand of RNA that is processed with the help of serine protease NS3 to produce mature virus. Inhibition of NS3 protease can be potentially used to develop effective drugs for HCV infections. Numerous efforts are now underway to develop potent inhibitors of HCV protease that contain ketoamides as serine traps. Herein we report the synthesis of a series of potent inhibitors that contain a boronic acid as a serine trap. The activity of these compounds were optimized to 200pM. X-ray structure of compound 17 bound to NS3 protease is also discussed. Potent inhibitors of HCV-NS3 protease derived from boronic acids.,Venkatraman S, Wu W, Prongay A, Girijavallabhan V, George Njoroge F Bioorg Med Chem Lett. 2009 Jan 1;19(1):180-3. Epub 2008 Nov 5. PMID:19022670[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||